Immix Biopharma Inc

NASDAQ IMMX

Data sourced from

and

Daily

Download Data

Immix Biopharma Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Immix Biopharma Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Immix Biopharma Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Immix Biopharma Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Immix Biopharma Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: IMMX

Immix Biopharma Inc

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
IPO Date	Dec. 16, 2021
Location	United States
Headquarters	11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Employees	14
Sector	Healthcare
Industry	Biotechnology

Description

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Key trends